These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 21771992)
41. Future prospects for pharmacogenetics in the quest for personalized medicine. Howland RH J Psychosoc Nurs Ment Health Serv; 2012 Dec; 50(12):13-6. PubMed ID: 23457712 [TBL] [Abstract][Full Text] [Related]
42. Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). Picard N; Boyer JC; Etienne-Grimaldi MC; Barin-Le Guellec C; Thomas F; Loriot MA; Therapie; 2017 Apr; 72(2):185-192. PubMed ID: 28237406 [TBL] [Abstract][Full Text] [Related]
43. Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital. La Russa R; Fineschi V; Di Sanzo M; Gatto V; Santurro A; Martini G; Scopetti M; Frati P Curr Pharm Biotechnol; 2017; 18(3):274-281. PubMed ID: 28176638 [TBL] [Abstract][Full Text] [Related]
44. Human genetics: international projects and personalized medicine. Apellaniz-Ruiz M; Gallego C; Ruiz-Pinto S; Carracedo A; Rodríguez-Antona C Drug Metab Pers Ther; 2016 Mar; 31(1):3-8. PubMed ID: 26581075 [TBL] [Abstract][Full Text] [Related]
45. The Future of Precision Medicine. Verstegen RHJ; Ito S Clin Pharmacol Ther; 2019 Nov; 106(5):903-906. PubMed ID: 31584718 [TBL] [Abstract][Full Text] [Related]
46. Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic? Huddart R; Sangkuhl K; Whirl-Carrillo M; Klein TE Clin Pharmacol Ther; 2019 Aug; 106(2):284-286. PubMed ID: 30977517 [No Abstract] [Full Text] [Related]
49. Understanding the Pathogenesis, Therapeutic Targets/Drug Action and Pharmacogenetics of Type 2 Diabetes: Is there a Future for Personalised Medicine? Engwa GA; Nweke FN; Karngong GN; Afiukwa CA; Nwagu KE Endocr Metab Immune Disord Drug Targets; 2020; 20(10):1569-1589. PubMed ID: 32334506 [TBL] [Abstract][Full Text] [Related]
54. Advances in the Pharmacogenomics of Adverse Drug Reactions. Collins SL; Carr DF; Pirmohamed M Drug Saf; 2016 Jan; 39(1):15-27. PubMed ID: 26650062 [TBL] [Abstract][Full Text] [Related]
56. Personalized medicine without the "omics". Kravitz RL J Gen Intern Med; 2014 Apr; 29(4):551. PubMed ID: 24504920 [No Abstract] [Full Text] [Related]
57. Precision Medicine 2.0: The Next Wave of Science. Dandara C; Özdemir V OMICS; 2016 Oct; 20(10):555-556. PubMed ID: 27726641 [No Abstract] [Full Text] [Related]
58. Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care. Trent RJ; Cheong PL; Chua EW; Kennedy MA Pathology; 2013 Jun; 45(4):357-70. PubMed ID: 23594690 [TBL] [Abstract][Full Text] [Related]
59. Pharmacogenomics in pediatrics: personalized medicine showing eminent promise. Mele C; Goldschmidt K J Pediatr Nurs; 2014; 29(4):378-82. PubMed ID: 24880100 [No Abstract] [Full Text] [Related]
60. Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy. Udagawa C; Zembutsu H Cancer Sci; 2020 Oct; 111(10):3445-3457. PubMed ID: 32780457 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]